Browse EX-10 agreements

September 9, 2026

Dr. Rui Zhu

[***]

**Re: Confirmatory Offer Letter **

Dear Rui,

You are currently employed by ADARx Pharmaceuticals, Inc. (the “Company”) as Chief Technology Officer. This letter confirms the terms and conditions of your employment in that role.

| | |

…

**ADARX PHARMACEUTICALS, INC. **

**2026 EQUITY INCENTIVE PLAN **

**ADOPTED BY THE BOARD OF DIRECTORS: SEPTEMBER 13, 2026 **

**APPROVED BY THE STOCKHOLDERS: SEPTEMBER 16, 2026 **

1.	**GENERAL. **

(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve plus any Returning Shares will become available for issuance pursuant to Awards granted under this Plan; and (iii) all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding Awards result in Returning Shares that become available for issuance pursuant to Awards granted under this Plan). All Awards granted under this Plan will be subject to the terms of this Plan.

…

**ADARX PHARMACEUTICALS, INC. **

**STOCK OPTION GRANT NOTICE **

**(2026 EQUITY INCENTIVE PLAN) **

ADARx Pharmaceuticals, Inc. (the “Company”), pursuant to its 2026 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein and in the Plan, and the Stock Option Agreement and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable.

…

September 10, 2026

Dr. Zhen Li

[***]

**Re: Confirmatory Offer Letter **

Dear Zhen,

You are currently employed by ADARx Pharmaceuticals, Inc. (the “Company”) as Chief Executive Officer. This letter confirms the terms and conditions of your employment in that role.

| | |

…

September 9, 2026

Rob Ackles

[***]

**Re: Confirmatory Offer Letter **

Dear Rob,

You are currently employed by ADARx Pharmaceuticals, Inc. (the “Company”) as Chief People Officer. This letter confirms the terms and conditions of your employment in that role.

| | |

…

September 9, 2026

Dr. Robert MacLeod

[***]

**Re: Confirmatory Offer Letter **

Dear Robert,

You are currently employed by ADARx Pharmaceuticals, Inc. (the “Company”) as Chief Scientific Officer. This letter confirms the terms and conditions of your employment in that role.

| | |

…

**ADARX PHARMACEUTICALS, INC. **

**NON-EMPLOYEE DIRECTOR COMPENSATION POLICY **

Each member of the Board of Directors (the “Board”) of ADARx Pharmaceuticals, Inc. (the “Company”) who is not also serving as an employee of or consultant to the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for his or her Board service upon and following the date of the underwriting agreement between the Company and the underwriters managing the initial public offering of the Company’s common stock (the “Common Stock”), pursuant to which the Common Stock is priced in such initial public offering (the “Effective Date”). An Eligible Director may decline all or any portion of his or her or their compensation by giving notice to the Company prior to the date cash may be paid or equity awards are to be granted, as the case may be. This Policy is effective as of the Effective Date and may be amended at any time in the sole discretion of

…

**ADARX PHARMACEUTICALS, INC. **

**SEVERANCE PLAN **

**AND **

**SUMMARY PLAN DESCRIPTION **

**APPROVED BY THE BOARD OF DIRECTORS: SEPTEMBER 2, 2026 **

1. Introduction. The purpose of this ADARx Pharmaceuticals, Inc. Severance Plan (the “Plan”) is to provide specified severance benefits to eligible employees of the Company (as defined below) whose employment is terminated by the Company or a successor under certain circumstances. This Plan is an “employee welfare benefit plan,” as defined in Section 3(1) of ERISA (as defined below). This Plan shall supersede any existing severance plan or individual agreement between the Company and any Covered Employee (as defined below) and any other plan, policy or practice, whether written or unwritten, maintained by the Company with respect to a Covered Employee, in each case to the extent that such agreement, plan, policy or practice provides for equity acceleration or severance benefits upon the Covered Employee’s separation from the Company; provided, however, that notwithstanding anything to the contrary herein, this Plan shall not

…

**ADARX PHARMACEUTICALS, INC. **

**2026 EMPLOYEE STOCK PURCHASE PLAN **

**ADOPTED BY THE BOARD OF DIRECTORS: SEPTEMBER 13, 2026 **

**APPROVED BY THE STOCKHOLDERS: SEPTEMBER 16, 2026 **

1.	**GENERAL; PURPOSE. **

(a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan.

…

September 11, 2026

Ryan Fisk

[***]

**Re: Confirmatory Offer Letter **

Dear Ryan,

You are currently employed by ADARx Pharmaceuticals, Inc. (the “Company”) as Chief Financial Officer and Chief Business Officer. This letter confirms the terms and conditions of your employment in that role.

| |

…